By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aduro Biotech 

626 Bancroft Way
Suite 3C
Berkeley  California  94710  U.S.A.
Phone: 510-848-4400 Fax: n/a


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
Aduro Biotech Presents Updated Interim Results From Phase 1b Clinical Trial In Mesothelioma At International Mesothelioma Interest Group Conference 10/24/2014 10:51:24 AM
Aduro Biotech Announces Interim Phase 1B Clinical Data Of CRS-207 For The Treatment Of Mesothelioma Accepted For Oral Presentation At The International Mesothelioma Interest Group Conference 10/16/2014 11:23:28 AM
Berkeley's Aduro Biotech Strikes $817 Million Lung Cancer Pact With Janssen Biotech Inc. (JNJ) 10/16/2014 6:50:36 AM
Aduro Biotech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., Featured Speaker On Action Of Vaccine Adjuvants At Keystone Symposia 10/9/2014 10:49:25 AM
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/21/2014 6:37:52 AM
Aduro Biotech Names Industry Veteran And Academic Leader, Gerald Chan, DSc To Its Board Of Directors 7/17/2014 8:05:29 AM
With Johnson & Johnson (JNJ) Deals, Berkeley's Aduro Biotech Gets New Chance To Prove Worth 6/18/2014 7:59:43 AM
Berkeley's Aduro Biotech Reels In $55 Million Series C Financing 6/11/2014 3:04:04 PM
Aduro Biotech Announces American Society of Clinical Oncology Presentation Of Promising Results From Phase 1b Clinical Trial Of Its Novel Immunotherapy For The Treatment Of Mesothelioma 6/2/2014 10:46:52 AM
Johnson & Johnson (JNJ)'s Janssen Biotech Inc. (JNJ) Licenses LADD From Bay Area's Aduro Biotech In Deal Worth $365 Million 5/29/2014 7:36:19 AM
12345
//-->